Australia's Botanix Pharmaceuticals rises on $30 million debt facility with Kreos Capital
10/06/2025 04:02
** Botanix Pharmaceuticals BOT.AX rises 8.3% to A$0.3575, set for its best day since April 29, if trends sustain ** The clinical dermatology co signs $30 million debt facility with London-headquartered Kreos Capital ** Says new debt facility will support commercialisation of its lead product Sofdra, used to treat excessive sweating in the armpits ** Stock down 19% this year, including the session's moves (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.SinghChundawat@thomsonreuters.com))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million